| 22.05 17:40 | Valbiotis launches its e-commerce site for the marketing of Valbiotis®PRO Cholestérol |
| 26.04 07:30 | Valbiotis publishes its annual accounts 2023 |
| 26.04 07:30 | Valbiotis publishes its annual accounts 2023 -2- |
| 03.04 08:30 | Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May |
| 03.04 08:30 | Valbiotis to launch its 100% natural dietary -2- |
| 29.01 17:40 | Valbiotis presents its 2024 financial communication calendar |
| 16.01 17:40 | Valbiotis sets out its commercial and clinical roadmap for 2024 |
| 16.01 17:40 | Valbiotis sets out its commercial and clinical -2- |
| 22.12 07:35 | Valbiotis announces the success of its EUR15 M capital increase |
| 22.12 07:35 | Valbiotis announces the success of its EUR15 M -2- |
| 22.12 07:35 | Valbiotis announces the success of its EUR15 M -3- |
| 11.12 21:04 | Valbiotis announces the launch of a capital -2- |
| 11.12 21:04 | Valbiotis announces the launch of a capital -3- |
| 11.12 21:04 | Valbiotis announces the launch of a capital increase |
| 11.12 20:23 | Valbiotis announces the availability of an amendment to the Universal Registration Document |
| 11.12 20:02 | Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status |
| 04.12 17:40 | VALBIOTIS SA: |
| 07.11 17:40 | Valbiotis announces the success of the TOTUM.63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes |
| 07.11 17:40 | Valbiotis announces the success of the TOTUM.63 -2- |
| 02.10 17:40 | VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes |
|
|
